Stay updated with breaking news from Daniel Gaudet. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol - Data presented at European Atherosclerosis Society 92nd Congress...
Daniel Gaudet, MD, PhD, discusses SHASTA-2 data and what cardiologists could learn from the forthcoming 48-week MUIR trial data from EAS 2024.
In Bridge-TIMI 73a and SHASTA-2, the RNA-silencing therapies cut triglycerides quickly, offering hope for hard-to-treat patients.
In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.
Novel drug shows promise for treating severe hypertriglyceridemia in patients at high risk for pancreatitis